RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect
Open Access
- 1 June 2019
- journal article
- research article
- Published by Armenian Green Publishing Co. in Iranian Journal of Biotechnology
- Vol. 17 (2), 8-13
- https://doi.org/10.21859/ijb.2008
Abstract
Background: Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half-life and bioavailability. Objectives: In this study, the in vitro cytotoxicity and hemocompatibility of RGD-modified nano-liposomes (RGD-MNL) encapsulated a highly potent antiplatelet drug (eptifibatide) was investigated. Material and Methods: RGD-MNL encapsulated eptifibatide was prepared using lipid film hydration and freeze/thawing method. The morphology and size distribution (about 90 nm) of RGD-MNL were characterized using transmission electron microscopy (TEM). The in-vitro cytotoxicity of nano-liposomes was examined using the MTT, LDH release and reactive oxygen species (ROS) generation assays. The effect of RGD-MNL on red blood cells (RBC) was investigated using hemolysis and LDH release assays. Results: The results revealed that RGD-MNL had no significant cytotoxic effect on HeLa and HUVEC cell lines, and also no ROS generation increase in the cells. In addition, the adverse effect of RGD-MNL on LDH release and membrane integrity of RBC was not observed. Conclusions: In conclusion, the recommended RGD-MNL formulations have not any significant cytotoxicity on normal cells or RBC and have potential for protecting and enhancing the activity of antiplatelet drugs.Keywords
This publication has 26 references indexed in Scilit:
- In vitro and in vivo platelet targeting by cyclic RGD‐modified liposomesJournal of Biomedical Materials Research Part A, 2009
- Targeted delivery of thrombolytic agents: role of integrin receptorsExpert Opinion on Drug Delivery, 2009
- The role of nanoparticle size in hemocompatibilityToxicology, 2009
- Liposomes for targeted delivery of antithrombotic drugsExpert Opinion on Drug Delivery, 2008
- Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated plateletsBiomaterials, 2008
- Multivariate toxicity screening of liposomal formulations on a human buccal cell lineInternational Journal of Pharmaceutics, 2007
- Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory propertiesJournal of Vascular Surgery, 2006
- Mitochondrial free radical generation, oxidative stress, and agingFree Radical Biology & Medicine, 2000
- Integrin receptors and platelet adhesion to synthetic surfacesJournal of Biomedical Materials Research, 1993
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983